ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse

ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse

Patients with ulcerative colitis (UC) may experience nonresponse to biologics, possibly as a result of low drug exposure. This trial assessed the efficacy of dose optimization in patients with UC who have early nonresponse to vedolizumab and high drug clearance. ENTERPRET was a phase 4, open-label,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2024-05, Vol.22 (5), p.1077-1086.e13
Hauptverfasser: Jairath, Vipul, Yarur, Andres, Osterman, Mark T., James, Alexandra, Balma, Diane, Mehrotra, Shailly, Yang, Lili, Yajnik, Vijay, Qasim Khan, Rana M.
Format: Artikel
Sprache:eng
Schlagworte:
Dose Optimization
Endoscopic Improvement
Therapeutic Drug Monitoring
Ulcerative Colitis
Vedolizumab
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with ulcerative colitis (UC) may experience nonresponse to biologics, possibly as a result of low drug exposure. This trial assessed the efficacy of dose optimization in patients with UC who have early nonresponse to vedolizumab and high drug clearance. ENTERPRET was a phase 4, open-label, randomized, controlled trial that included patients with moderate to severe UC who had high drug clearance at week 5 (serum concentration,
ISSN:1542-3565
1542-7714
1542-7714
DOI:10.1016/j.cgh.2023.10.029